Breaking News

Jubilant, Sanofi in Strategic Metabolic Alliance

January 7, 2016

Aims to develop small molecules to address unmet needs in diabetes and obesity

Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, have entered a strategic alliance to discover and develop small molecule inhibitors for multiple targets in metabolic disorders. The research alliance aims to develop therapeutic small molecules that will address the unmet needs in diabetes and obesity.
Jubilant will provide drug discovery and early development services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism. The research for the projects take place at R&D labs of Jubilant Biosys and Jubilant Chemsys (Noida, India).
Dr. Sriram Rajagopal, chief scientific officer, Jubilant Biosys said, "We are excited to partner with Sanofi, one of the global healthcare leader, to offer our integrated drug discovery solutions. Over the past few years, we have been strengthening our therapeutic area expertise in the scientific perspective and this collaboration is a validation of our efforts. This alliance demonstrates Jubilant's commitment to global innovation and we look forward to a long mutually beneficial partnership."
Dr. Philip Just Larsen, vice president, global head of Diabetes Research & Translational Medicine, Sanofi Deutschland GmbH said, "The collaboration with Jubilant underscores our commitment to engaging innovators around the world, as we develop the next generation of improved therapies for people with diabetes."

Related Compliance: